Leukemia
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)
- Details
ClinicalTrials.gov ID:
NCT06001788
Diagnosis Type:
NA
USOR Number:
- Address
,
P: